Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.